Introduction of Vaccinomics to Develop Personalized Vaccines in Light of Changes in the Usage of Hantaan Virus Vaccine (Hantavax®) in Korea

다국어 초록 (Multilingual Abstract)

The Ministry of Food and Drug Safety of Korea made an official announcement in March 2018 that the total number of inoculations of Hantaan virus vaccine (Hantavax®) would change from 3 to 4. Some aspects of this decision remain controversial. Based on the characteristics of Hantaan virus (HTNV) and its role in the pathogenesis of hemorrhagic fever with renal syndrome, it might be difficult to develop an effective and safe HTNV vaccine through the isolate-inactivate-inject paradigm. With the development of high-throughput ‘omics’ technologies in the 21st century, vaccinomics has been introduced. While the goal of vaccinomics is to develop equations to describe and predict the immune response, it could also serve as a tool for developing new vaccine candidates and individualized approaches to vaccinology. Thus, the possibility of applying the innovative field of vaccinomics to develop a more effective and safer HTNV vaccine should be considered.

참고문헌 (Reference)

1 Gaucher D, "Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses" 205 (205): 3119-3131, 2008

2 Poland GA, "Vaccinomics, adversomics, and the immune response network theory : individualized vaccinology in the 21st century" 25 (25): 89-103, 2013

3 Poland GA, "Vaccinology in the third millennium : scientific and social challenges" 17 : 116-125, 2016

4 Nakaya HI, "Vaccinology in the era of high-throughput biology" 370 (370): 20140146-, 2015

5 De Gregorio E, "Vaccines for the future : learning from human immunology" 5 (5): 149-155, 2012

6 Schmaljohn CS, "Vaccines for hantaviruses : progress and issues" 11 (11): 511-513, 2012

7 Petrizzo A, "Systems vaccinology for cancer vaccine development" 13 (13): 711-719, 2014

8 Hagan T, "Systems vaccinology : enabling rational vaccine design with systems biological approaches" 33 (33): 5294-5301, 2015

9 Pulendran B, "Systems vaccinology" 33 (33): 516-529, 2010

10 Ackerman ME, "Systems serology for evaluation of HIV vaccine trials" 275 (275): 262-270, 2017

11 Mooney M, "Systems immunogenetics of vaccines" 25 (25): 124-129, 2013

12 Oberg AL, "Systems biology approaches to new vaccine development" 23 (23): 436-443, 2011

13 Querec TD, "Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans" 10 (10): 116-125, 2009

14 Circelli L, "Systems biology approach for cancer vaccine development and evaluation" 3 (3): 544-555, 2015

15 오수진, "Systems Biology-Based Platforms to Accelerate Research of Emerging Infectious Diseases" 연세대학교의과대학 59 (59): 176-186, 2018

16 Jung J, "Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome" 217 (217): 1417-1420, 2018

17 Park K, "Protective effectiveness of hantavirus vaccine" 10 (10): 2218-2220, 2004

18 Sohn YM, "Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine(Hantavax) : consideration of active immunization in South Korea" 42 (42): 278-284, 2001

19 Poland GA, "Personalized vaccines : the emerging field of vaccinomics" 8 (8): 1659-1667, 2008

20 Ministry of Food and Drug Safety, "Online library of drugs and foods"

21 Oh MD, "Milestones in history of adult vaccination in Korea" 1 (1): 9-17, 2012

22 Krüger DH, "Human pathogenic hantaviruses and prevention of infection" 7 (7): 685-693, 2011

23 Poland GA, "Heterogeneity in vaccine immune response : the role of immunogenetics and the emerging field of vaccinomics" 82 (82): 653-664, 2007

24 Maes P, "Hantaviruses : immunology, treatment, and prevention" 17 (17): 481-497, 2004

25 Avšič-Županc T, "Hantavirus infections" 21S : e6-e16, 2019

26 이용진, "Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome" 대한신장학회 37 (37): 366-372, 2018

27 Halloran ME, "Design and interpretation of vaccine field studies" 21 (21): 73-88, 1999

28 Mooney M, "A systems framework for vaccine design" 25 (25): 551-555, 2013

29 Chu YK, "A field efficacy trial of inactivated hantaan virus vaccine(Hantavax(TM))against hemorrhagic fever with renal syndrome(HFRS)in the endemic areas of Yugoslavia from 1996 to 1998" 29 (29): 55-64, 1999